Check for updates

REVIEW

REVISED Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease [version 2; peer review: 2 approved]

Catherine Baker ¹, Matthew S. Hayden^{1,2}¹Geisel School of Medicine at Dartmouth, Hanover, NH, 03755, USA²Section of Dermatology, Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03766, USA

v2 First published: 23 Apr 2020, 9:281
<https://doi.org/10.12688/f1000research.23185.1>

Latest published: 07 Oct 2020, 9:281
<https://doi.org/10.12688/f1000research.23185.2>

Abstract

The discovery of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system has revolutionized gene editing research. Through the repurposing of programmable RNA-guided CRISPR-associated (Cas) nucleases, CRISPR-based genome editing systems allow for the precise modification of specific sites in the human genome and inspire novel approaches for the study and treatment of inherited and acquired human diseases. Here, we review how CRISPR technologies have stimulated key advances in dermatologic research. We discuss the role of CRISPR in genome editing for cutaneous disease and highlight studies on the use of CRISPR-Cas technologies for genodermatoses, cutaneous viruses and bacteria, and melanoma. Additionally, we examine key limitations of current CRISPR technologies, including the challenges these limitations pose for the widespread therapeutic application of CRISPR-based therapeutics.

Keywords

CRISPR, dermatology, gene editing, genodermatoses, viruses, cutaneous disease

Open Peer Review

Approval Status

	1	2
version 2 (revision) 07 Oct 2020		view

version 1 23 Apr 2020	view	view

1. **Bindu Hegde**, University of California, San Francisco, San Francisco, USA

2. **Jillian Richmond** , University of Massachusetts Medical School, Worcester, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Matthew S. Hayden (Matthew.S.Hayden@Hitchcock.org)

Author roles: Baker C: Data Curation, Investigation, Writing – Original Draft Preparation; Hayden MS: Conceptualization, Supervision, Writing – Original Draft Preparation

Competing interests: Hayden MS has received research funding from Excision Biotherapeutics.

Grant information: This work was supported by the American Skin Association (C.B.) and the Hitchcock Foundation (M.S.H.).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Baker C and Hayden MS. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Baker C and Hayden MS. **Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease [version 2; peer review: 2 approved]** F1000Research 2020, 9:281 <https://doi.org/10.12688/f1000research.23185.2>

First published: 23 Apr 2020, 9:281 <https://doi.org/10.12688/f1000research.23185.1>

REVISED Amendments from Version 1

This updated version has an expanded "Perspectives and Future Directions" section, which now includes more details on the role of CRISPR in the cutaneous microbiome and engineered T-cell therapies. Challenges to clinical application of CRISPR therapeutics are also explored in further detail.

Any further responses from the reviewers can be found at the end of the article

Introduction

Gene editing technologies have been transformative in biological research and show immense potential for the study and treatment of inherited and acquired human diseases¹. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system uses programmable RNA-guided CRISPR-associated (Cas) nucleases to change, remove, or add genetic material to specific locations within the genome². In comparison with other site-specific nucleases, such as zinc finger nucleases (ZFNs), meganucleases (MNs), and transcription activator-like effector nucleases (TALENs), CRISPR-Cas nucleases are easier to design and implement through the simple manipulation of a guide RNA sequence.

Dermatologic conditions hold particular appeal as targets for CRISPR-Cas therapeutics. There are several well-described, monogenic inherited skin disorders, such as the epidermal blistering disorders, that are considered ideal candidates for genome editing therapeutics. In addition, the skin is an easily accessible organ that allows for extraction and *in vitro* culture of target cells as well as direct localized administration of CRISPR-Cas therapeutics through topical, grafting or injection methods³. Lastly, for the same reason, the visibility of skin allows for simpler monitoring of the genetically edited cutaneous tissues for both efficacy and potential deleterious effects³.

Ongoing research efforts are exploring a variety of CRISPR-Cas approaches to the development of new CRISPR-Cas therapeutics for dermatology. Though most experiments have focused on *ex vivo* manipulation of diseased primary cell lines, researchers are increasingly developing *in vivo* and *ex vivo* techniques with translational potential. We propose that, for a variety of reasons, dermatology is likely to continue to be at the center of the development and clinical application of CRISPR-Cas therapeutics. For example, one of the first human trials involving CRISPR-Cas9 is geared toward treating refractory melanoma, among other neoplasms⁴. Therefore, in this review we will focus on the current research and potential future applications of therapeutic CRISPR-Cas nucleases in dermatology.

Mechanisms of genome engineering with CRISPR-Cas

There are several types of CRISPR-Cas systems (I-III), and numerous subtypes, that have been identified in bacteria and archaea, but the type II CRISPR-Cas9 system is the best studied, particularly in terms of its application to dermatology therapeutics⁵. The type II CRISPR system provides bacteria

with a mechanism of immunologic memory and defense against foreign DNA⁶. Using CRISPR, bacteria incorporate short sequences of exogenous DNA from invading pathogens, for example from bacteriophages or viruses that infect bacteria, into their own genome. When transcribed from the bacterial host genome, these sequences are processed into CRISPR RNAs (crRNAs) that complex with a *trans*-activating crRNA (tracrRNA). The crRNA/tracrRNA duplex directs Cas9 to cleave target double-stranded DNA that is complementary to the 20-nucleotide guide sequence within the crRNA, creating a site-specific double strand break (DSB). In the laboratory, a single 80 to 100-nucleotide RNA transcript synthesized in the form of a single guide RNA (sgRNA) can mimic the structure and function of the crRNA/tracrRNA duplex (Figure 1)². The simplicity and multiplexing capacity of CRISPR-Cas9 nuclease activity is based on the easy-to-design sgRNA or crRNA, whose RNA sequences can be modified to direct the Cas nuclease to target different sequences in the dsDNA genome.

In eukaryotic cells, following the formation of a site-specific DSB by Cas9, one of two cellular repair processes can occur: non-homologous end joining (NHEJ) or homology-directed repair (HDR) (Figure 1)⁷. NHEJ is an error-prone process that can result in mutations or nucleotide insertions and deletions (indels), interrupting the sequence of a target gene. In contrast, HDR is a high-fidelity DNA repair strategy whereby the DSB is repaired using homologous DNA as a template. HDR can be facilitated by co-administration of homologous donor DNA with the Cas nuclease. This donor sequence can be used as a synthetic template for the cell to copy when repairing the Cas-induced DSB. HDR can be used to direct the repair of a mutated gene, albeit with lower efficiency than NHEJ⁸. Approaches are still being developed to improved HDR efficiency, which currently is found to vary widely depending on the target and targeting approach^{9,10}.

To date, most genome engineering strategies for dermatological disease have involved the *ex vivo* editing of patient-derived primary cells (Figure 1)¹¹. To perform *ex vivo* editing, patient cells are isolated and genetically modified *in vitro*, potentially for subsequent autologous transplantation. This strategy allows for the clonal selection, characterization, and expansion of genetically modified cells prior to use for engraftment in the affected organ or tissue. *Ex vivo* approaches facilitate targeting and delivery of the CRISPR-Cas therapeutic and, by allowing for enrichment of modified cells, reduce the requirement for highly efficient and specific CRISPR-Cas editing constructs¹². However, cell expansion in culture can lead to unwanted cellular differentiation, particularly in induced pluripotent stem cells (iPSCs)¹³. In addition, cell-based transplantations can be technologically challenging, especially for non-hematopoietic cells. In contrast to *ex vivo* gene manipulation, *in vivo* gene editing involves the direct modification of somatic cells *in situ* (Figure 1). Using CRISPR-Cas constructs, *in vivo* gene editing is achieved through systemic or local administration of packaged CRISPR-Cas components (protein, DNA, and/or RNA) into the body to induce gene editing outcomes in specific

A Mechanisms of genome editing with CRISPR-Cas9

B Strategies for gene modification therapies in humans

C Traditional gene therapy: Gene augmentation

Genome Editing with CRISPR-Cas

Figure 1. CRISPR-Cas9 gene editing strategies. (A) Mechanism of CRISPR-Cas9 genome editing. Cas9 nuclease complexes with a single guide RNA (sgRNA) to form a ribonucleoprotein (RNP). The sgRNA guides Cas9 to create a double strand break (DSB) three to four base pairs proximal to an "NGG" PAM sequence. After creating a DSB, dsDNA can be repaired by either non-homologous end joining (NHEJ) or, when a homologous dsDNA donor template is available, homology-directed repair (HDR). (B) Strategies for gene modification therapies in humans. *Ex vivo* gene editing strategies involve the extraction and manipulation of patient-derived cells *in vitro* in cell culture. Gene-corrected cells are expanded in culture and are subsequently re-infused or grafted onto the patient. *In vivo* gene editing involves the direct delivery of CRISPR-Cas DNA, RNA, and/or protein via viral or nonviral means. (C) Traditional gene therapy versus genome editing with CRISPR-Cas technology. Traditional gene therapy involves the addition of a functioning gene to replace a mutant allele. The replacement gene is usually inserted randomly into the host genome via a viral vector. In contrast, genome editing with CRISPR-Cas involves the direct, site-specific editing of the host genome.

organs or cells. *In vivo* editing requires the development of effective targeting strategies to generate cell-specific changes with minimal off-target effects and precludes comprehensive characterization of all edited cells. Safe *in vivo* gene editing techniques could have utility for a wide range of systemic and localized diseases, but many hurdles and concerns remain to be addressed.

Genodermatoses

Most genodermatoses are monogenic in nature and therefore serve as an attractive disease model for gene therapy¹⁴. Because there are no widely available effective treatments for these disorders, current therapies are focused primarily on symptom management. Early success in the use of gene therapy for the treatment of the monogenic inherited epidermolysis bullosa (EB) disorders provided particular promise for the development of curative therapies for genodermatoses. In 2006, a patient suffering from nonlethal junctional EB (JEB) underwent successful long-term skin transplantation with epidermal sheets made from gene-corrected autologous keratinocytes^{15,16}. These keratinocytes were corrected using a retroviral vector encoding the beta 3 chain of laminin-332, compensating for the mutated version of the gene in this patient. Such successes laid the groundwork for further research in gene replacement and gene editing strategies for cutaneous disorders. Unlike classically defined gene therapy, which involves the random insertion of one or more exogenous genes into cells to replace the function of a missing or mutated gene, gene editing involves the direct, site-specific manipulation of the genome using targeted nucleases such as ZFNs, TALENs, and CRISPR-Cas enzymes (Figure 1)¹⁷. The therapeutic potential of direct genome manipulation is immense. Researchers have leveraged CRISPR-Cas constructs to develop diverse treatment strategies for genodermatoses including the targeted addition of genes to specific genomic sites, the correction of disease-causing point mutations, and the removal of disease-causing genes or genomic sequences. Such strategies allow for corrective gene editing and the targeted ‘knockout’ of mutant alleles in dominant negative disorders. It is also hoped that targeted gene editing strategies will reduce the risks associated with random insertion of exogenous transgenes.

EB. Of the genodermatoses, the inherited EB disorders have been the most extensively studied as potential candidates for gene editing therapy³. The EB disorders are a diverse group of inherited blistering diseases that affect the skin and, in some subtypes, mucous membranes and other organs¹⁸. They are caused by mutations in over 20 different genes that code for different proteins expressed at the cutaneous basement membrane zone¹⁹.

Two EB subtypes—EB Simplex (EBS) and dominant dystrophic EB (DDEB)—are caused by dominant negative mutations that cannot be corrected with traditional additive gene therapies. Thus, these disorders are particularly well-suited for treatment with CRISPR-Cas genome editing, which allows for the direct modification of the dominant, disease-causing allele. EBS is caused by dominant negative missense mutations in either the keratin 14 (*KRT14*) or keratin 5 (*KRT5*) genes that code for

intermediate filaments (IFs) expressed in the basal layer of the epidermis^{20,21}. Kocher *et al.*²² used CRISPR-Cas9-induced HDR to correct the disease-causing mutated *KRT14* allele in EBS patient keratinocytes *in vitro*. Gene-corrected clones showed normal phenotype without characteristic mutant cytoplasmic aggregates in cell culture. DDEB is caused by dominant negative mutations in *COL7A1*, which codes for collagen 7 (C7)^{23,24}. Shinkuma *et al.*²⁵ successfully used CRISPR-Cas9 to induce site-directed mutagenesis of the mutated *COL7A1* allele in iPSCs derived from DDEB patient keratinocytes. Edited cells expressed a truncated version of C7 that was incapable of forming deleterious trimers with WT C7 and would hypothetically allow for normal anchoring fibril formation at the DEJ²⁵.

Unlike EBS and DDEB, JEB and RDEB are inherited in an autosomal recessive manner. Therefore, CRISPR-Cas therapeutics for these disorders must achieve gene correction to allow for production of new, functional proteins. This can be accomplished through precise correction of the disruptive mutation (i.e., via CRISPR-Cas9 induced HDR with a gene-corrected donor template) or through methods that produce a functional protein without fully correcting the disease-causing mutation. For example, in specific cases, targeted deletions can be used to either remove a premature stop codon or causative mutation directly or to disrupt splicing signals, allowing for therapeutic exon skipping. JEB is caused by autosomal recessive mutations in genes encoding subunits of the heterotrimeric laminin-5 (laminin-332) protein (e.g., *LAMA3*, *LAMB3*, and *LAMC2*)^{26,27}, and RDEB is caused by autosomal recessive mutations in *COL7A1*^{28,29}. For both of these conditions, CRISPR-Cas9-mediated HDR has been used to successfully correct disease-causing mutations *ex vivo* in patient-derived primary keratinocytes^{30–33} and iPSCs³⁴. When grafted onto immunodeficient mice, gene-corrected keratinocytes displayed restored WT functionality and adhesion at the DEJ^{31–33}. However, the efficiency of HDR during *ex vivo* gene modification remains low, particularly without antibiotic selection protocols or other methods of enriching for modified cells. Exon skipping approaches have been explored for the treatment of RDEB. Exon 80 contains a common disease-causing point mutation in the *COL7A1* gene³⁵. By inducing targeted Cas9-mediated DSBs on either side of the mutation-bearing exon 80 in *COL7A1*, it is possible to mediate complete excision of the disease-causing mutation. Bonafant *et al.* delivered paired Cas9/sgRNA RNPs to patient keratinocytes *ex vivo* through electroporation. They were able to achieve efficient rates of deletion of exon 80, generating cells with restored C7 expression that, when grafted to immunodeficient mice, showed long-term dermal-epidermal adhesion³⁶.

Notably, Cas9-mediated therapies for RDEB have recently expanded to include *in vivo* approaches, with Wu and colleagues³⁷ restoring C7 function in an RDEB mouse model using the exon skipping approach. Wu *et al.* designed two sgRNAs targeting the 5' and 3' side of exon 80 and delivered them as an sgRNA/Cas9 ribonucleoprotein complex (RNP) via intradermal injection into mouse tail skin. They then directly electroporated the mouse tail to facilitate penetration of RNPs into epidermal stem cells.

By causing DSBs on either side of the mutation-bearing exon 80 in COL7A1, they were able to achieve complete excision of the disease-causing mutation in epidermal stem cells. Electroporated mice displayed restored C7 function, and their dermal-epidermal adhesion area improved from 30% to 60% after one treatment³⁷. The success of this approach demonstrated the potential for CRISPR-Cas9-induced gene correction of epidermal stem cells *in vivo* without the cost and technical challenge of *ex vivo* cell modification. Still, however, several limitations of this method are apparent. Only 2% of epidermal cells were capable of being targeted with this novel *in vivo* delivery method, and no long-term follow-up to assess sustainability of the treatment could be performed. Moreover, potential off-target effects of the Cas9/sgRNA RNPs at sites other than exon 80 were not analyzed. Whether transdermal delivery of Cas9/sgRNA RNPs via electroporation would be safe and effective in humans has yet to be explored. However, it is likely that considerable pain and collateral damage may be associated with transdermal electroporation techniques³⁸, particularly for EB patients. Electroporation protocols for EB patients would require high voltages to penetrate the nuclei of epidermal stem cells and would need to be administered over large surface areas of skin.

Epidermolytic palmoplantar keratoderma (EPPK). EPPK is an autosomal dominant keratin disease of the hereditary palmoplantar keratoderma (PPK) group characterized by an abnormal thickening of skin on the palms and soles³⁹. The disease is caused by dominant-negative missense mutations in the *KRT9* gene, leading to the formation of a mutant keratin 9 (K9) protein that interferes with the function of the wild-type K9⁴⁰. EPPK has relatively localized disease manifestations that are well suited for targeted delivery of CRISPR therapeutics.

Luan and colleagues showed that through local delivery of a lentiviral (LV) vector carrying an sgRNA and Cas9 directed to the mutant *KRT9* allele, they could disrupt the formation of the mutant K9 protein *in vivo* in an EPPK mouse model and induce phenotypic correction of the disease⁴⁰. Mice who received nine subcutaneous injections of the Cas9/sgRNA-containing LV particles into their right forepaw over the course of 24 days displayed restored epidermal proliferation of the forepaw and a reduction in disease-associated K9 expression. Off-target effects of the genome editing system were reportedly minimal, but analyses were limited to 10 predicted off-target sites in the mouse genome⁴⁰. In addition, long-term effects of the treatment on the mice were not recorded, and there was no analysis of potential immune response to the LV Cas9 vector—an occurrence which has been reported for other LV vector systems⁴¹. Still, this study demonstrates the potential for robust *in vivo* effects of CRISPR-Cas9-mediated gene editing, particularly for diseases that have localized manifestations.

Cutaneous viruses

CRISPR-Cas systems, which evolved in bacteria to fight invading bacteriophages, have also been repurposed to serve a similar function in virally infected human cells. In human cells, CRISPR-Cas enzymes have the potential to target latent viruses

that are able to escape eradication by immune surveillance and standard antiviral therapies. As such, there has been extensive research into the ability of CRISPR-Cas systems to target specific viral genomic sequences, enabling targeted disruption and even complete excision of components of the viral genome⁴². In addition, researchers have leveraged the high sensitivity of certain Cas enzymes for the purposes of viral pathogen detection in human tissue samples⁴³. Cas12 and Cas13—two Cas enzymes that demonstrate indiscriminate trans-cleavage of ssDNA when activated by their guide-complementary target nucleotide sequence—enable ultrasensitive nucleic acid detection in viral biosensing systems such as DETECTR⁴⁴, SHERLOCK/SHERLOCKv2⁴⁵ and HOLMES/HOLMESv2^{46,47}.

Though most CRISPR-mediated antiviral research to date has focused on systemic viruses that lack primary cutaneous involvement, the unique accessibility of the skin suggests that CRISPR therapeutics and diagnostics might be more effectively applied to cutaneous viruses. Current research suggests CRISPR-Cas technology may be effective in detecting and modifying human papillomavirus (HPV), herpes simplex virus (HSV), and Kaposi sarcoma-associated herpesvirus (KSHV).

HPV. HPV is a dsDNA virus that infects the basal cells of stratified epithelium. Here, the virus has the potential to integrate its viral DNA into the host genome. The HPV E6 and E7 proteins of certain high-risk strains, including 16, 18, 31, 33, cause malignant transformation of epithelial cells by inactivating p53 and Rb, respectively^{48,49}, and can lead to anogenital squamous cancers and other neoplasms. E7 expression from lower risk strains of HPV, particularly strains 6 and 11, is associated with the uncontrolled proliferation of epithelial cells that cause genital warts^{50,51}.

Several researchers have effectively used CRISPR-Cas9 to disrupt of E6 and E7 genes in cervical cancer cells, both *in vitro* and *in vivo* in animal models^{47–49,52–54}. One of the first antiviral CRISPR-Cas9 clinical trial in humans will involve *in vivo* targeting of E6/E7 in HPV-infected neoplastic cervical cells⁵⁵.

Though fewer studies have been performed with the aim of using CRISPR-Cas to cure the dermatological manifestations of HPV, researchers have begun to develop CRISPR-Cas constructs targeting the virus in HPV-associated anal cancer and genital warts. Hsu *et al.*⁵⁶ were able to successfully decrease tumor burden in a mouse model of HPV-16-associated anal cancer. Using an adeno-associated virus (AAV) vector, they delivered Cas9 nuclease in conjunction with two gRNAs: one gRNA specific for HPV-16 E6 and the other specific for HPV-16 E7. When delivered via three intratumoral injections over one week to mice with patient-derived xenografts of HPV-16 anal cancer cells, the CRISPR-Cas9 and dual-gRNA caused a twofold decrease in tumor volume, providing proof of concept for a novel *in vivo* gene editing strategy for HPV-16-associated anal cancer. For HPV-associated genital warts, CRISPR-Cas9 has been used to successfully target the E7 gene *in vitro*, promoting apoptosis of HPV-6 and -11-infected keratinocyte cell lines⁵⁷. Notably, however, the Cas9 and gRNAs were transfected

transiently into the keratinocyte cell line and achieved only incomplete E7 deactivation. In addition, efficacy of the genome editing construct was not confirmed *in vivo*.

CRISPR-Cas systems hold potential for not only HPV therapeutics, but also HPV diagnostics. DETECTR is a nucleic acid biosensing system that uses the enzyme Cas12a and a ssDNA fluorescent reporting scheme to identify specific sequences in amplified dsDNA from human samples⁴⁴. Chen *et al.*⁴⁴ showed that by using their DETECTR platform, they could detect human papillomavirus (HPV) DNA in patient anal swab samples with attomolar sensitivity, even reliably distinguishing between different genotypes of the virus. Moreover, their assay was performed in just one hour and involved only isothermal amplification of DNA, suggesting that DETECTR could serve as a rapid, low-cost, point-of-care detection assay for HPV with similar sensitivity and specificity to conventional diagnostic PCR.

Herpesviruses. The herpesviruses are large dsDNA viruses that establish lifelong infection in human hosts^{58,59}. HSV-1 and HSV-2 classically infect the oral and genital mucosal epithelium, respectively, leading to the local production of ulcers. After undergoing partial clearance by the host immune system, HSV establishes latent infection in the form of episomal DNA in sensory ganglia. KSHV, or human herpesvirus 8, infects human endothelial cells and is the causative agent of Kaposi's sarcoma⁶⁰. Like HSV and other herpesviruses, KSHV remains latent in most infected cells. Latent herpes infections avoid immunological surveillance by limiting viral gene transcription⁶¹ and are extremely difficult to treat.

As conventional therapies targeting viral replication are ineffective against latent virus, CRISPR-mediated targeting of viral DNA has emerged as an alternative approach for HSV, KSHV, and other herpesviruses. Roehm and colleagues⁶² were able to completely abrogate HSV-1 replication in human fibroblast cells *in vitro* by disrupting two essential viral genes using CRISPR-Cas9. Other researchers have achieved similar success against HSV-1, inhibiting viral replication *in vitro* in oligodendrogloma cells and epithelial cells using Cas9/gRNA editing complexes without evident off-target effects^{62,63}. For KSHV, researchers have demonstrated an ability to reduce the burden of KSHV in latently infected epithelial and endothelial cell lines by AAV-CRISPR-Cas9-mediated disruption of the KSHV latency-associated nuclear antigen (LANA)⁶⁴.

Still, challenges remain in the use of CRISPR-Cas for herpesviruses. First, despite demonstrated ability to abrogate active viral replication of HSV-1, it remains to be seen whether CRISPR-Cas can be effectively used to eradicate latent HSV-1 in neurons⁶⁵. Oh *et al.* were able to disrupt quiescent HSV-1 genomes, but at a much lower rate compared to HSV-1 virions in the lytic cycle⁶⁶. Because other targeted nucleases, such as MNs, have been shown to successfully target latent HSV-1 infection⁶⁷, it is suspected that current failure to eliminate latent HSV-1 using CRISPR-Cas9 may be due to epigenetic modifications of the latent HSV-1 genome that block Cas9

activity^{65,68}. Moreover, further demonstration of the effectiveness of anti-HSV and anti-KSHV CRISPR-Cas systems *in vivo* will also be important. For HSV-1 and -2, *in vivo* delivery may be simpler than for other systems because latent HSV-1 and 2 have very specific tropism for the trigeminal and sacral ganglia, respectively, and possible delivery strategies could be designed to specifically home to these ganglia.

Cutaneous bacterial infections

In addition to viral infections, CRISPR-Cas technology also shows promise against resistant bacterial infections^{69,70}. Bacterial infections that are resistant to common antibiotics represent a growing public health concern^{71,72}. Yet, despite this risk, antibiotics continue to be overprescribed⁷³ while the development of novel antimicrobials for new pathogens lags behind⁷⁴. Recently, CRISPR-Cas antimicrobials have emerged as a novel treatment strategy against bacterial infections^{69,70}. Specifically, CRISPR-Cas9 has been leveraged to selectively remove antimicrobial resistance genes from populations of bacteria, re-sensitizing populations of bacteria to common antimicrobials^{75,76}. Though systemic delivery of CRISPR-based antimicrobials remains a challenge, the accessibility of the skin enables the delivery of CRISPR constructs via convenient topical formulations⁶⁹ and places cutaneous bacterial infections at the forefront of CRISPR antimicrobial research.

Staphylococcus aureus. *Staphylococcus aureus*, a common cutaneous bacterial pathogen known for its antimicrobial resistance, is responsible for 76% of all skin and soft tissue infections⁷⁷ and is associated with high morbidity and mortality⁷⁸. Antimicrobial resistance to *S. aureus* continues to emerge as the pathogen gains plasmids and other mobile genetic elements that confer antibiotic resistance and virulence genes⁷⁹. Moreover, outbreaks remain common as the pathogen maintains a high prevalence in the population, asymptotically colonizing the nostrils of 20–30% of healthy adults⁸⁰.

Bikard and colleagues⁷⁵ developed a novel approach to target virulent strains of *S. Aureus* using CRISPR-Cas9. They developed gRNAs targeted to specific *S. Aureus* antimicrobial resistance genes, including the methicillin resistance gene, *mecA*. When delivered with Cas9 via a phage capsid to mixed populations of bacteria *in vitro*, these gRNA/Cas9 constructs were able to eradicate resistant *S. Aureus* strains and completely remove specific plasmids carrying antimicrobial resistance genes. Moreover, when delivered topically to a mouse model of *S. Aureus* skin colonization *in vivo*, these gRNA/Cas9 constructs were able to significantly decrease colonization by resistant bacteria. These results demonstrated promise for the topical application of CRISPR antimicrobials *in vivo* and laid the foundation for future multiplexed CRISPR antimicrobials designed to simultaneously target either several bacterial species or multiple gene sequences within the same bacterium. These results also demonstrated the potential for CRISPR antimicrobials to modulate the cutaneous microbiome. The role of the cutaneous microbiome in dermatologic disease continues to unfold as researchers analyze metagenomic sequencing data from varied skin samples⁸¹. For example, reduced microbiome

diversity and increased *S. aureus* skin colonization has been implicated in the pathogenesis of atopic dermatitis⁸². The potential role for CRISPR antimicrobials in atopic dermatitis patients has yet to be explored, but antimicrobials targeting pathogenic *S. aureus* strains may complement strategies designed to augment commensal bacterial populations in the cutaneous microbiome⁸³.

Melanoma

Some of the first CRISPR-Cas clinical trials in humans have involved the use of CRISPR-Cas technology in immunotherapy for cancers, including melanoma and non-small-cell lung cancer (NSCLC)⁴. Much of this research has centered on the use of gene editing to inactivate key immune checkpoint inhibitors such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)—two proteins that normally inhibit the anti-tumor cytotoxic effect of endogenous and exogenous T cells⁸⁴.

Melanoma is well-known to have exceptional immunogenic potential, owing largely to the high mutational burden that drives the formation of immune-stimulating neoantigens⁸⁵. Thus, under optimal conditions, melanoma cells are particularly susceptible to destruction by the human immune system⁸⁶. Yet, clinically, the tumor microenvironment in melanoma is highly immunosuppressive⁸⁷, and advanced disease has exceptionally poor treatment response⁸⁸. Consequently, melanoma serves as an ideal target for immunotherapies that are designed to relieve tumor immunosuppression.

The first human trial designed to test the use of CRISPR-Cas for melanoma builds on the demonstrated success of previous immunotherapies, including PD-1 inhibitors⁸⁹ and T cells transduced with the NY-ESO-1 T-cell receptor (TCR)⁹⁰. Specifically, researchers aim to amplify the therapeutic effects of these existing approaches by using CRISPR-Cas9 to knock out PD-1 gene loci in autologous NY-ESO-1 TCR-transduced T cells. Autologous T cells are first taken from a patient and transduced with a LV vector that expresses the NY-ESO-1 TCR, priming them to recognize a highly immunogenic NY-ESO-1 antigen expressed on melanoma cells⁹¹. They are then electroporated with RNA-guided CRISPR-Cas9 nucleases designed to disrupt the expression of both PD-1 and the endogenous TCR subunits, TCR α and TCR β ⁴. Disrupting PD-1 prevents immune suppressive signaling, and blocking the endogenous TCR subunits inhibits aberrant immune responses that may result from TCR-mediated targeting of unknown antigens. With re-introduction of these melanoma-targeted, immune-avid T cells, researchers hope to obtain a more robust tumor-specific immune response—a response that has been difficult to achieve with previous T-cell therapies for solid tumors⁹². Moreover, beyond having an enhanced anti-tumor effect, such an approach is also expected to minimize unwanted treatment side effects. Using this treatment model, PD-1 blockade will be limited to the specific TCR-transduced T-cells that are designed to home to and attack NY-ESO-1-expressing melanoma cells. This stands in contrast to traditional anti-PD1 receptor antibodies which, when administered systemically, have the potential to affect T-cells more broadly and cause widespread immunogenic side effects⁹³.

Perspectives and future directions

Taken together, a wide variety of studies underscore the potential for CRISPR-based therapeutics for genodermatoses, cutaneous infections, and melanoma. Future research will likely continue to expand on this success, with the aim of increasing the translatability of CRISPR therapeutics as well as developing expanded strategies to target other dermatologic diseases.

There are many other genetic skin disorders and cutaneous infections that could be targeted with CRISPR-Cas therapeutics. Pachyonychia congenita and xeroderma pigmentosum have been targeted with RNAi-based therapies⁹⁴ and designer nucleases⁹⁵, respectively, and could likely also be targeted with CRISPR-based genome engineering. Rare cases of EB are caused by multiple co-occurring mutations^{96–99} and could be treated with unique CRISPR-Cas constructs targeting several genetic loci⁴. Moreover, with the advent of hypoinmunogenic universal donor iPSCs—iPSCs that are genetically modified by CRISPR-Cas9 to avoid inciting a host immune response^{100,101}—existing *ex vivo* gene modification strategies for genodermatoses could be applied to patients more broadly. Despite concern for the tumorigenic potential of iPSC¹⁰², CRISPR-edited iPSCs were not associated with tumorigenesis in a mouse model of RDEB32. By optimizing the re-differentiation process of iPSCs and excluding cells with oncogenic potential, iPSCs may prove safe for clinical application¹⁰³.

There are many cutaneous viruses that hold promise for targeting with gene editing technologies, including the oncoviruses, Merkel-cell polyomavirus (MCPyV), and human T-cell leukemia virus type 1 (HTLV-1). MCPyV causes up to 80% of Merkel cell carcinomas (MCC) and is randomly integrated into different sites in the MCC tumor genome¹⁰⁴. Excision of MCPyV from MCC tumor cells could represent a potential therapeutic strategy for aggressive MCCs that are often refractory to many current therapies^{104–106}. Preliminary studies in Merkel cell cancer cell lines demonstrate that CRISPR-Cas9-mediated disruption of the MCPyV tumor antigens leads to diminished cell growth¹⁰⁷. HTLV-1, the retrovirus that causes HTLV-1-associated/tropical spastic myelopathy and adult T cell leukemia/lymphoma, has yet to be explored as a target for CRISPR-Cas therapeutics. Studies focusing on HIV^{108–111}—a similarly structured retrovirus—would suggest that HTLV-1 could likely be completely excised from infected cells using CRISPR-Cas9. The relative genetic conservation of HTLV-1 relative to HIV-1¹¹² would make it an even more appropriate candidate for targeting by RNA-guided endonucleases.

As engineered T cell therapies continue to expand, clinical trials will begin to test the use of increasingly safe and effective CRISPR-edited TCR-transduced and chimeric antigen receptor (CAR) T cells for melanoma. CRISPR gene editing technology will facilitate the creation of universal donor T cells with disrupted endogenous TCR and human leukocyte antigens class I (HLA-Is)¹¹³, allowing T cells extracted from healthy donors to be used for the treatment of patients with any HLA type. In addition, T cell therapies will become safer and more controllable through the addition of inducible safety genes to genetically engineered T cells. For example, cells engineered with an inducible caspase-9 gene will undergo apoptosis in the

presence of the small molecule inducer AP1903¹¹⁴. This “kill switch” allows for drug- or small-molecule-induced inactivation of edited cells in the case of an adverse reaction.

Lastly, CRISPR-Cas technology will likely develop clinical utility in the diagnosis of dermatological disease. CRISPR-Cas diagnostic platforms using Cas9¹¹⁵, Cas12^{44,46,116}, Cas13⁴⁵, and Cas14¹¹⁷ have the potential to revolutionize the detection of nucleic acid sequences, allowing for the ultrasensitive, low-cost, and portable detection of cutaneous viruses and single point mutations in cutaneous tumors^{117,118}.

Challenges to therapeutic application

There remain several challenges to the widespread application of CRISPR-based therapeutics. The studies reported here largely demonstrate the ability of CRISPR-Cas systems to treat human disease both in cell culture models and through *ex vivo* modification of primary patient cell lines. While such methods currently represent the safest approach to gene editing in humans, such a technique is technologically challenging and of limited use for routine clinical practice. *In vivo* treatment options would be ideal, but fewer studies have explored these possibilities. Studies on the *in vivo* treatment of non-dermatologic disorders, including Duchenne muscular dystrophy^{119–121}, hereditary liver disease^{122–124}, congenital eye disease¹²⁵, and Huntington Disease¹²⁶ have shown tremendous promise in animal models. However, of the studies in dermatology focused on *in vivo* delivery of CRISPR-therapeutics, all have been limited to localized effects in mouse models, and none have demonstrated high efficiency or success in long-term follow up^{37,40,56}.

For *in vivo* genome editing via CRISPR-Cas technology to be clinically translatable not only in dermatology but also in other fields, there are several major challenges that are yet to be effectively addressed. CRISPR-Cas guide RNAs and nucleases must 1) be optimized for robust and specific on-target effects with minimal off-target effects, 2) be delivered efficiently to specific human cells, and 3) have minimal antigenic properties so that they are accepted by human immune systems¹²⁷. Novel CRISPR-Cas enzymes and delivery systems are being developed to tackle these challenges. To improve specificity of CRISPR-Cas9, researchers have modified Cas9 construction¹²⁸, optimized sgRNA design¹²⁹, and developed a CRISPR-Cas9 double nickase approach¹³⁰ that introduces only single-strand nicks at target

sites. Newly developed Cas9 variants (enhanced specificity Cas9 [eSpCas9]¹³¹, high-fidelity Cas9 [Cas9-HF1]¹²⁸, hyper-accurate Cas9 [HypaCas9]¹³², evoCas9¹³³, and xCas9¹³⁴) allow for improved gene editing specificity. HDR efficiency is augmented by chemical NHEJ inhibitors⁸, modified HDR templates, and polymer-stabilized Cas9 RNPs¹³⁵. In addition, researchers have developed sensitive methods to scan the entire genome for unintended off-target genome editing effects, including GUIDE-Seq¹³⁶, Digenome-seq¹³⁷, SITE-seq¹³⁸, CIRCLE-Seq¹³⁹, and, most recently, VIVO¹⁴⁰. Such methods would allow for screening of off-target effects of a given Cas/gRNA construct prior to therapeutic use.

Novel delivery methods are also being explored that expand upon traditional AAV- and LV-associated delivery systems. Gene delivery methods with viral vectors have the potential to cause integrational mutagenesis and lifelong Cas9 expression in cells. For this reason, delivery of Cas9 nuclease by way of a transiently expressed Cas9/sgRNA RNP may be preferred. Scientists have developed lipid nanoparticles that can carry CRISPR-Cas nucleotide sequences or RNP complexes that are targeted to specific organs^{141–143}. Still, it will be challenging to achieve systemic delivery of such therapies, particularly for bloodborne illnesses that would require the delivery of CRISPR-Cas constructs to every circulating B or T cell¹⁴².

Lastly, to limit the possible immunologic response to Cas9 by preformed antibodies in human serum¹⁴⁴, researchers have discovered novel Cas enzymes such as the structurally distinct Cas12e and Cas12d from ground bacteria¹⁴⁵. CRISPR therapeutics employing nucleases from bacteria to which humans are not exposed may not be subject to pre-existing immunity, allowing for a more robust genome editing effect.

Conclusion

Though significant work remains to be done prior to its widespread therapeutic use in humans, preliminary research suggests great potential for CRISPR-Cas technology in the treatment of dermatological pathologies. As researchers continue to optimize delivery methods and off-target screening approaches, more human trials for the treatment of dermatologic diseases with CRISPR-based gene editing therapeutics will likely be initiated.

Data availability

No data are associated with this study.

References

1. Finn JD, Smith AR, Patel MC, *et al.*: **A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent *In Vivo* Genome Editing**. *Cell Rep.* 2018; **22**(9): 2227–2235. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Jinek M, Chylinski K, Fonfara I, *et al.*: **A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity**. *Science.* 2012; **337**(6096): 816–821. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Lwin SM, McGrath JA: **Gene Therapy for Inherited Skin Disorders**. ELS John Wiley & Sons. 2017. [Publisher Full Text](#)
4. Stadtmayer E: **Phase 1 Trial of Autologous T Cells Engineered to Express**

- NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells).** Clinicaltrials.Gov. NCT03399448. 2018.
[Reference Source](#)
5. Jiang F, Doudna JA: **CRISPR-Cas9 Structures and Mechanisms.** *Annu Rev Biophys.* 2017; **46**: 505–529.
[PubMed Abstract](#) | [Publisher Full Text](#)
 6. Damian M, Porteus MH: **A Crisper Look at Genome Editing: RNA-guided Genome Modification.** *Mol Ther.* 2013; **21**(4): 720–722.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 7. Symington LS, Gautier J: **Double-Strand Break End Resection and Repair Pathway Choice.** *Annu Rev Genet.* 2011; **45**: 247–271.
[PubMed Abstract](#) | [Publisher Full Text](#)
 8. Maruyama T, Dougan SK, Truttmann MC, et al.: **Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.** *Nat Biotechnol.* 2015; **33**(5): 538–542.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. Tang XD, Gao F, Liu MJ, et al.: **Methods for Enhancing Clustered Regularly Interspaced Short Palindromic Repeats/Cas9-Mediated Homology-Directed Repair Efficiency.** *Front Genet.* 2019; **10**: 551.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 10. Miyaoka Y, Berman JR, Cooper SB, et al.: **Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing.** *Sci Rep.* 2016; **6**: 23549.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Gorell E, Nguyen N, Lane A, et al.: **Gene therapy for skin diseases.** *Cold Spring Harb Perspect Med.* 2014; **4**(4): a015149.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Dai WJ, Zhu LY, Yan ZY, et al.: **CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles.** *Mol Ther - Nucleic Acids.* 2016; **5**: e349.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Savić N, Schwank G: **Advances in therapeutic CRISPR/Cas9 genome editing.** *Transl Res.* 2016; **168**: 15–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Lehmann J, Seebode C, Emmert S: **Research on genodermatoses using novel genome-editing tools.** *J Dtsch Dermatol Ges.* 2017; **15**(8): 783–789.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Mavilio F, Pellegrini G, Ferrari S, et al.: **Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.** *Nat Med.* 2006; **12**(12): 1397–402.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. De Rosa L, Carulli S, Cocchiarella F, et al.: **Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa.** *Stem Cell Rep.* 2014; **2**(1): 1–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Maeder ML, Gersbach CA: **Genome-editing Technologies for Gene and Cell Therapy.** *Mol Ther.* 2016; **24**(3): 430–446.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Fine JD, Bruckner-Tuderman L, Eady RAJ, et al.: **Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.** *J Am Acad Dermatol.* 2014; **70**(6): 1103–1126.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Uitto J, Bruckner-Tuderman L, McGrath JA, et al.: **EB2017-Progress in Epidermolysis Bullosa Research toward Treatment and Cure.** *J Invest Dermatol.* 2018; **138**(5): 1010–1016.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Bonifas JM, Rothman AL, Epstein EH: **Epidermolysis bullosa simplex: evidence in two families for keratin gene abnormalities.** *Science.* 1994; **254**(5035): 1202–1205.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Coulombe PA, Hutton ME, Letal A, et al.: **Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses.** *Cell.* 1991; **66**(6): 1301–1311.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Kocher T, Peking P, Klaussegger A, et al.: **Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.** *Mol Ther.* 2017; **25**(11): 2585–2598.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Christiano AM, Greenspan DS, Hoffman GG, et al.: **A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa.** *Nat Genet.* 1993; **4**(1): 62–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Hilal L, Rochat A, Duquesnoy P, et al.: **A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa.** *Nat Genet.* 1993; **5**(3): 287–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Shinkuma S, Guo Z, Christiano AM: **Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa.** *Proc Natl Acad Sci U S A.* 2016; **113**(20): 5676–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Uitto J, Pulkkinen L, Christiano AM: **Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes.** *J Invest Dermatol.* 1994; **103**(5 Suppl): S39–S46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Nakano A, Chao SC, Pulkkinen L, et al.: **Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes.** *Hum Genet.* 2002; **110**(1): 41–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Bruckner-Tuderman L, Mitsuhashi Y, Schnyder UW, et al.: **Anchoring Fibrils and Type VII collagen are Absent From Skin in Severe Recessive Dystrophic Epidermolysis Bullosa.** *J Invest Dermatol.* 1989; **93**(1): 3–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Soro L, Bartus C, Purcell S: **Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies.** *J Clin Aesthet Dermatol.* 2015; **8**(5): 41–46.
[PubMed Abstract](#) | [Free Full Text](#)
 30. Webber BR, Osborn MJ, McElroy AN, et al.: **CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.** *NPJ Regen Med.* 2016; **1**: 16014.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Benati D, Miselli F, Cocchiarella F, et al.: **CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.** *Mol Ther.* 2018; **26**(11): 2592–2603.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Hainzl S, Peking P, Kocher T, et al.: **COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.** *Mol Ther.* 2017; **25**(11): 2573–2584.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Izmiryan A, Ganier C, Bovolenta M, et al.: **Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.** *Mol Ther Nucleic Acids.* 2018; **12**: 554–567.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Jacków J, Guo Z, Hansen C, et al.: **CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.** *Proc Natl Acad Sci U S A.* 2019; **116**: 26846–26852.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Escámez MJ, García M, Cuadrado-Corrales N, et al.: **The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation.** *Br J Dermatol.* 2010; **163**(1): 155–161.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Bonafont J, Mencía Á, García M, et al.: **Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.** *Mol Ther.* 2019; **27**(5): 986–998.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Wu W, Lu Z, Li F, et al.: **Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.** *Proc Natl Acad Sci U S A.* 2017; **114**(7): 1660–1665.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Hui SW: **Overview of Drug Delivery and Alternative Methods to Electroporation.** In: Li S, editor. *Electroporation Protocols: Preclinical and Clinical Gene Medicine.* Totowa, NJ: Humana Press; 2008; 91–107.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Has C, Technau-Hafsi K: **Palmoplantar keratoderms: clinical and genetic aspects.** *J Dtsch Dermatol Ges.* 2016; **14**(2): 123–140. quiz 140.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Luan XR, Chen XL, Tang YX, et al.: **CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse.** *Mol Ther Nucleic Acids.* 2018; **12**: 220–228.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Nayak S, Herzog RW: **Progress and prospects: immune responses to viral vectors.** *Gene Ther.* 2010; **17**(3): 295–304.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. de Buhr H, Lebbink RJ: **Harnessing CRISPR to combat human viral infections.** *Curr Opin Immunol.* 2018; **54**: 123–129.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Li Y, Li S, Wang J, et al.: **CRISPR/Cas Systems towards Next-Generation Biosensing.** *Trends Biotechnol.* 2019; **37**(7): 730–743.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Chen JS, Ma E, Harrington LB, et al.: **CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity.** *Science.* 2018; **360**(6387): 436–439.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Gootenberg JS, Abudayyeh OO, Kellner MJ, et al.: **Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6.** *Science.* 2018; **360**(6387): 439–444.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Li SY, Cheng QX, Wang JM, et al.: **CRISPR-Cas12a-assisted nucleic acid detection.** *Cell Discov.* 2018; **4**: 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Teng F, Guo L, Cui T, et al.: **CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity.** *Genome Biol.* 2019; **20**(1): 132.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Mürger K, Baldwin A, Edwards KM, et al.: **Mechanisms of human**

- papillomavirus-induced oncogenesis.** *J Virol.* 2004; **78**(21): 11451–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Hoppe-Seyler K, Bossler F, Braun JA, et al.: **The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.** *Trends Microbiol.* 2018; **26**(2): 158–168.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Jacobs MV, de Roda Husman AM, van den Brule AJ, et al.: **Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes.** *J Clin Microbiol.* 1995; **33**(4): 901–905.
[PubMed Abstract](#) | [Free Full Text](#)
 51. Chelimo C, Wouldes TA, Cameron LD, et al.: **Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer.** *J Infect.* 2013; **66**(3): 207–217.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Zhen S, Hua L, Takahashi Y, et al.: **In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.** *Biochem Biophys Res Commun.* 2014; **450**(4): 1422–1426.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Kennedy EM, Kornepati AV, Goldstein M, et al.: **Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.** *J Virol.* 2014; **88**(20): 11965–11972.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Zhen S, Lu JJ, Wang LJ, et al.: **In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.** *Transl Oncol.* 2016; **9**(6): 498–504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Lau CH, Suh Y: **In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease [version 1; peer review: 2 approved].** *F1000Res.* 2017; **6**: 2153.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Hsu DS, Kornepati AV, Glover W, et al.: **Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo.** *Future Virol.* 2018; **13**(7): 475–482.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Liu YC, Cai ZM, Zhang XJ: **Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes.** *Asian J Androl.* 2016; **18**(3): 475–479.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Whitley RJ, Roizman B: **Herpes simplex virus infections.** *Lancet.* 2001; **357**(9267): 1513–1518.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Azwa A, Barton SE: **Aspects of herpes simplex virus: a clinical review.** *J Fam Plann Reprod Health Care.* 2009; **35**(4): 237–242.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Mesri EA, Cesarman E, Boshoff C: **Kaposi's sarcoma and its associated herpesvirus.** *Nat Rev Cancer.* 2010; **10**(10): 707–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Grinde B: **Herpesviruses: latency and reactivation - viral strategies and host response.** *J Oral Microbiol.* 2013; **5**: 22766.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Roehm PC, Shekarabi M, Wollbo HS, et al.: **Inhibition of HSV-1 Replication by Gene Editing Strategy.** *Sci Rep.* 2016; **6**: 23146.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Lin C, Li H, Hao M, et al.: **Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells.** *Sci Rep.* 2016; **6**: 34531.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Tso FY, West JT, Wood C: **Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.** *J Virol.* 2019; **93**(7): pii: e02183-18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. van Diemen FR, Lebbink RJ: **CRISPR/Cas9, a powerful tool to target human herpesviruses.** *Cell Microbiol.* 2017; **19**(2): e12694.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Oh HS, Neuhauser WM, Eggan P, et al.: **Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9.** *eLife.* 2019; **8**: pii: e51662.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Aubert M, Madden EA, Loprieno M, et al.: **In vivo disruption of latent HSV by designer endonuclease therapy.** *JCI Insight.* 2016; **1**(14): pii: e88468.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. Oh HS, Neuhauser WM, Eggan P, et al.: **Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9.** *eLife.* 2019; **8**: pii: e51662.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Greene AC: **CRISPR-Based Antibacterials: Transforming Bacterial Defense into Offense.** *Trends Biotechnol.* 2018; **36**(2): 127–130.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Pursey E, Sünderhauf D, Gaze WH, et al.: **CRISPR-Cas antimicrobials: Challenges and future prospects.** *PLoS Pathog.* 2018; **14**(6): e1006990.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Roca I, Akova M, Baquero F, et al.: **The global threat of antimicrobial resistance: science for intervention.** *New Microbes New Infect.* 2015; **6**: 22–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Aslam B, Wang W, Arshad MI, et al.: **Antibiotic resistance: a rundown of a global crisis.** *Infect Drug Resist.* 2018; **11**: 1645–1658.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Llor C, Bjerrum L: **Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.** *Ther Adv Drug Saf.* 2014; **5**(6): 229–241.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Fischbach MA, Walsh CT: **Antibiotics for emerging pathogens.** *Science.* 2009; **325**(5944): 1089–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Bikard D, Euler CW, Jiang W, et al.: **Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.** *Nat Biotechnol.* 2014; **32**(11): 1146–1150.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Citorik RJ, Mimee M, Lu TK: **Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.** *Nat Biotechnol.* 2014; **32**(11): 1141–1145.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Moran GJ, Krishnasadan A, Gorwitz RJ, et al.: **Methicillin-resistant *S. aureus* infections among patients in the emergency department.** *N Engl J Med.* 2006; **355**(7): 666–674.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Parlet CP, Brown MM, Horswill AR: **Commensal Staphylococci Influence *Staphylococcus aureus* Skin Colonization and Disease.** *Trends Microbiol.* 2019; **27**(6): 497–507.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Weigel LM, Donlan RM, Shin DH, et al.: **High-level vancomycin-resistant *Staphylococcus aureus* isolates associated with a polymicrobial biofilm.** *Antimicrob Agents Chemother.* 2007; **51**(1): 231–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Graham PL 3rd, Lin SX, Larson EL: **A U.S. population-based survey of *Staphylococcus aureus* colonization.** *Ann Intern Med.* 2006; **144**(5): 318–325.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Byrd AL, Belkaid Y, Segre JA: **The human skin microbiome.** *Nat Rev Microbiol.* 2018; **16**(3): 143–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Paller AS, Kong HH, Seed P, et al.: **The microbiome in patients with atopic dermatitis.** *J Allergy Clin Immunol.* 2019; **143**(1): 26–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 83. Nakatsuji T, Chen TH, Narala S, et al.: **Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic dermatitis.** *Sci Transl Med.* 2017; **9**(378): eaah4680.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Buchbinder EI, Desai A: **CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.** *Am J Clin Oncol.* 2016; **39**(1): 98–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Ko JS: **The Immunology of Melanoma.** *Clin Lab Med.* 2017; **37**(3): 449–471.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Maio M: **Melanoma as a model tumour for immuno-oncology.** *Ann Oncol.* 2012; **23** Suppl 8: viii10–viii14.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Zou W: **Immunosuppressive networks in the tumour environment and their therapeutic relevance.** *Nat Rev Cancer.* 2005; **5**(4): 263–274.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Maverakis E, Cornelius LA, Bowen GM, et al.: **Metastatic melanoma - a review of current and future treatment options.** *Acta Derm Venereol.* 2015; **95**(5): 516–524.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. Topalian SL, Hodi FS, Brahmer JR, et al.: **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.** *N Engl J Med.* 2012; **366**(26): 2443–2454.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 90. Robbins PF, Morgan RA, Feldman SA, et al.: **Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.** *J Clin Oncol.* 2011; **29**(7): 917–924.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 91. Baylis F, McLeod M: **First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?** *Curr Gene Ther.* 2017; **17**(4): 309–319.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 92. Simon B, Uslu U: **CAR-T cell therapy in melanoma: A future success story?** *Exp Dermatol.* 2018; **27**(12): 1315–1321.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Postow MA, Sidlow R, Hellmann MD: **Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.** *N Engl J Med.* 2018; **378**(2): 158–168.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Bornert O, Peking P, Bremer J, et al.: **RNA-based therapies for genodermatoses.** *Exp Dermatol.* 2017; **26**(1): 3–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

95. Dupuy A, Valton J, Leduc S, *et al.*: **Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALENTM**. *PLoS One*. 2013; **8**(11): e78678.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Padalon-Brauch G, Amitai DB, Vodo D, *et al.*: **Digenic Inheritance in Epidermolysis Bullosa Simplex**. *J Invest Dermatol*. 2012; **132**(12): 2852–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Wertheim-Tysarowska K, Oldak M, Giza A, *et al.*: **Novel sporadic and recurrent mutations in KRT5 and KRT14 genes in Polish epidermolysis bullosa simplex patients: further insights into epidemiology and genotype-phenotype correlation**. *J Appl Genet*. 2016; **57**(2): 175–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Kim E, Harris A, Bingham LJ, *et al.*: **A Review of 52 Pedigrees with Epidermolysis Bullosa Simplex Identifying Ten Novel Mutations in KRT5 and KRT14 in Australia**. *Acta Derm Venereol*. 2017; **97**(9): 1114–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Vahidnezhad H, Youssefian L, Saeidian AH, *et al.*: **Next generation sequencing identifies double homozygous mutations in two distinct genes (*EXPH5* and *COL17A1*) in a patient with concomitant simplex and junctional epidermolysis bullosa**. *Hum Mutat*. 2018; **39**(10): 1349–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Deuse T, Hu X, Gravina A, *et al.*: **Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients**. *Nat Biotechnol*. 2019; **37**(3): 252–258.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Han X, Wang M, Duan S, *et al.*: **Generation of hypoimmunogenic human pluripotent stem cells**. *Proc Natl Acad Sci U S A*. 2019; **116**(21): 10441–10446.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. Dinella J, Koster M, Koch P: **Use of Induced Pluripotent Stem Cells in Dermatological Research**. *J Invest Dermatol*. 2014; **134**(8): 1–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Attwood SW, Edel MJ: **iPS-Cell Technology and the Problem of Genetic Instability-Can It Ever Be Safe for Clinical Use?** *J Clin Med*. 2019; **8**(3): 288.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Feng H, Shuda M, Chang Y, *et al.*: **Clonal integration of a polyomavirus in human Merkel cell carcinoma**. *Science*. 2008; **319**(5866): 1096–1100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Martel-Jantin C, Filippone C, Cassar O, *et al.*: **Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma**. *Virology*. 2012; **426**(2): 134–142.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Sastre-Garau X, Peter M, Avril MF, *et al.*: **Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis**. *J Pathol*. 2009; **218**(1): 48–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Temblador A, Topalis D, Andrei G, *et al.*: **CRISPR/Cas9 Editing of the Polyomavirus Tumor Antigens Inhibits Merkel Cell Carcinoma Growth *In Vitro***. *Cancers*. 2019; **11**(9): pii: E1260.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. Ebina H, Misawa N, Kanemura Y, *et al.*: **Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus**. *Sci Rep*. 2013; **3**: 2510.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Hu W, Kaminski R, Yang F, *et al.*: **RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection**. *Proc Natl Acad Sci U S A*. 2014; **111**(31): 11461–11466.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. Liao HK, Gu Y, Diaz A, *et al.*: **Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells**. *Nat Commun*. 2015; **6**: 6413.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Kaminski R, Chen Y, Fischer T, *et al.*: **Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing**. *Sci Rep*. 2016; **6**: 22555.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Gasmil M, D'Incan M, Desgranges C: **Transfusion transmission of human T-lymphotropic virus type I (HTLV-I) from an asymptomatic blood donor: conservation of LTR U3, *env*, and *tax* nucleotide sequences in a recipient with HTLV-I-associated myelopathy**. *Transfusion*. 1997; **37**(1): 60–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
113. Liu X, Zhang Y, Cheng C, *et al.*: **CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells**. *Cell Res*. 2017; **27**(1): 154–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Gargett T, Brown MP: **The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells**. *Front Pharmacol*. 2014; **5**: 235.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Hajian R, Balderston S, Tran T, *et al.*: **Detection of unamplified target genes via CRISPR-Cas9 immobilized on a graphene field-effect transistor**. *Nat Biomed Eng*. 2019; **3**(6): 427–437.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Li L, Li S, Wang J: **CRISPR-Cas12b-assisted nucleic acid detection platform**. *BioRxiv*. 2018.
[Publisher Full Text](#)
117. Harrington LB, Burstein D, Chen JS, *et al.*: **Programmed DNA destruction by miniature CRISPR-Cas14 enzymes**. *Science*. 2018; **362**(6416): 839–842.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. Teng F, Guo L, Cui T, *et al.*: **CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity**. *Genome Biol*. 2019; **20**(1): 132.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Nelson CE, Hakim CH, Ousterout DG, *et al.*: ***In vivo* genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy**. *Science*. 2016; **351**(6271): 403–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Tabebordbar M, Zhu K, Cheng JKW, *et al.*: ***In vivo* gene editing in dystrophic mouse muscle and muscle stem cells**. *Science*. 2016; **351**(6271): 407–411.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Long C, Amoasii L, Mireault AA, *et al.*: **Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy**. *Science*. 2016; **351**(6271): 400–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Singh K, Evens H, Nair N, *et al.*: **Efficient *In Vivo* Liver-Directed Gene Editing Using CRISPR/Cas9**. *Mol Ther*. 2018; **26**(5): 1241–1254.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Yin H, Song CQ, Dorkin JR, *et al.*: **Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components *in vivo***. *Nat Biotechnol*. 2016; **34**(3): 328–333.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Yang Y, Wang L, Bell P, *et al.*: **A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice**. *Nat Biotechnol*. 2016; **34**(3): 334.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Ruan GX, Barry E, Yu D, *et al.*: **CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10**. *Mol Ther*. 2017; **25**(2): 331–341.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
126. Yang S, Chang R, Yang H, *et al.*: **CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease**. *J Clin Invest*. 2017; **127**(7): 2719–2724.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Cornu TI, Mussolino C, Cathomen T: **Refining strategies to translate genome editing to the clinic**. *Nat Med*. 2017; **23**(4): 415–423.
[PubMed Abstract](#) | [Publisher Full Text](#)
128. Kleinstiver BP, Pattanayak V, Prew MS, *et al.*: **High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects**. *Nature*. 2016; **529**(7587): 490–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Doench JG, Fusi N, Sullender M, *et al.*: **Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9**. *Nat Biotechnol*. 2016; **34**(2): 184–191.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
130. Ran FA, Hsu PD, Lin CY, *et al.*: **Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity**. *Cell*. 2013; **154**(6): 1380–1389.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Slaymaker IM, Gao L, Zetsche B, *et al.*: **Rationally engineered Cas9 nucleases with improved specificity**. *Science*. 2016; **351**(6268): 84–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
132. Chen JS, Dagdas YS, Kleinstiver BP, *et al.*: **Enhanced proofreading governs CRISPR-Cas9 targeting accuracy**. *Nature*. 2017; **550**(7676): 407–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
133. Casini A, Olivieri M, Petris G, *et al.*: **A highly specific SpCas9 variant is identified by *in vivo* screening in yeast**. *Nat Biotechnol*. 2018; **36**(3): 265–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. Hu JH, Miller SM, Geurts MH, *et al.*: **Evolved Cas9 variants with broad PAM compatibility and high DNA specificity**. *Nature*. 2018; **556**(7699): 57–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
135. Nguyen DN, Roth TL, Li PJ, *et al.*: **Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency**. *Nat Biotechnol*. 2020; **38**(1): 44–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
136. Tsai SQ, Zheng Z, Nguyen NT, *et al.*: **GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases**. *Nat Biotechnol*. 2014; **33**(2): 187–197.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. Kim D, Bae S, Park J, *et al.*: **Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells**. *Nat Methods*. 2015; **12**(3): 237–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
138. Cameron P, Settle AH, Fuller CK, *et al.*: **SITE-Seq: A Genome-wide Method to Measure Cas9 Cleavage**. 2017.
[Publisher Full Text](#)
139. Tsai SQ, Nguyen NT, Malagon-Lopez J, *et al.*: **CIRCLE-seq: a highly sensitive *in vitro* screen for genome-wide CRISPR-Cas9 nuclease off-targets**. *Nat Methods*. 2017; **14**(6): 607–614.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Akcakaya P, Bobbin ML, Guo JA, *et al.*: ***In vivo* CRISPR editing with no**

- detectable genome-wide off-target mutations.** *Nature.* 2018; **561**(7723): 416–419.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Zuris JA, Thompson DB, Shu Y, *et al.*: **Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing *in vitro* and *in vivo*.** *Nat Biotechnol.* 2015; **33**(1): 73–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 142. Jiang C, Mei M, Li B, *et al.*: **A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and *pcsk9* *in vivo*.** *Cell Res.* 2017; **27**(3): 440–443.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 143. Mout R, Ray M, Yesilbag Tonga G, *et al.*: **Direct Cytosolic Delivery of CRISPR/Cas9–Ribonucleoprotein for Efficient Gene Editing.** *ACS Nano.* 2017; **11**(3): 2452–2458.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 144. Charlesworth CT, Deshpande PS, Dever DP, *et al.*: **Identification of preexisting adaptive immunity to Cas9 proteins in humans.** *Nat Med.* 2019; **25**(2): 249–254.
[PubMed Abstract](#) | [Publisher Full Text](#)
 145. Burstein D, Harrington LB, Strutt SC, *et al.*: **New CRISPR-Cas systems from uncultivated microbes.** *Nature.* 2016; **542**(7640): 237–241.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 19 October 2020

<https://doi.org/10.5256/f1000research.29935.r72624>

© 2020 Richmond J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jillian Richmond

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA

Thank you for addressing my comments.

Competing Interests: JMR is an inventor on patent application #62489191, "Diagnosis and Treatment of Vitiligo", which covers targeting IL-15 and Trm for the treatment of vitiligo; and #15/851,651, "Anti-human CXCR3 antibodies for the Treatment of Vitiligo" which covers targeting CXCR3 for the treatment of vitiligo.

Reviewer Expertise: dermatology research, autoimmunity, skin diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 01 June 2020

<https://doi.org/10.5256/f1000research.25593.r63774>

© 2020 Richmond J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jillian Richmond

Department of Dermatology, University of Massachusetts Medical School, Worcester, MA, USA

In this review, Baker & Hayden describe the field of gene editing for the treatment of dermatologic

conditions. This is a very well-written and interesting review. I only have minor suggestions prior to publication.

Minor:

- In your discussion of NHEJ and HDR, could you provide specifics about the efficiency of HDR (as a freq, etc)?
- Under "Genodermatoses" you have a few sentences that seem redundant, please consider streamlining your intro paragraph before going into specific disease areas.
- Last paragraph under EB: any comment/concern about electroporating a mouse tail? Feasibility in humans? Side effects?
- In the melanoma section, any thoughts about "kill switch" T cells?
- Maybe include a brief discussion about the skin microbiome, either in the bacteria section or future directions section? Could focus on the impact of gene editing on microbiome dynamics, or therapeutic potential for correcting dysbioses.

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: JMR is an inventor on patent application #62489191, "Diagnosis and Treatment of Vitiligo", which covers targeting IL-15 and Trm for the treatment of vitiligo; and #15/851,651, "Anti-human CXCR3 antibodies for the Treatment of Vitiligo" which covers targeting CXCR3 for the treatment of vitiligo.

Reviewer Expertise: dermatology research, autoimmunity, skin diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 Sep 2020

Catherine Baker, Geisel School of Medicine at Dartmouth, Hanover, USA

Dear Dr. Richmond,

Thank you for your thoughtful review of our manuscript. We have carefully reviewed the comments and have revised the manuscript accordingly. Our responses are given in a point-by-point manner below.

1. In your discussion of NHEJ and HDR, could you provide specifics about the efficiency of HDR (as a freq, etc)?
 1. This is a difficult question because relative efficiencies of NHEJ and HDR vary quite widely depending on cell type and conditions. A sentence addressing this issue, as well as two references to articles addressing this topic, were added to the HDR/NHEJ discussion in "Mechanisms of genome engineering with CRISPR-Cas."
2. Under "Genodermatoses" you have a few sentences that seem redundant, please consider streamlining your intro paragraph before going into specific disease areas.
 1. Repetitive words/sentences were eliminated in this paragraph.
3. Last paragraph under EB: any comment/concern about electroporating a mouse tail? Feasibility in humans? Side effects?
 1. Two sentences on the feasibility of electroporation for human patients with EB were added.
4. In the melanoma section, any thoughts about "kill switch" T cells?
 1. A paragraph on engineered T-cell therapies, including "kill switch" T cells, was added to the "Perspectives and future directions" section.
5. Maybe include a brief discussion about the skin microbiome, either in the bacteria section or future directions section? Could focus on the impact of gene editing on microbiome dynamics, or therapeutic potential for correcting dysbioses.
 1. In "Cutaneous bacterial infections," a section on the potential role for CRISPR in modulating the cutaneous microbiome was added, particularly as it pertains to atopic dermatitis and *S. aureus* colonization.

Competing Interests: No competing interests were disclosed.

Reviewer Report 18 May 2020

<https://doi.org/10.5256/f1000research.25593.r62746>

© 2020 Hegde B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bindu Hegde

Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA

In this review article, Baker and Hayden discuss the role of CRISPR technology in genome editing

for dermatological diseases. Overall, the manuscript is well-written with clear and unambiguous language. The article highlights the studies that use CRISPR-Cas 9 approach for gene editing in various cutaneous diseases and provides a balanced assessment by noting both advantages and limitations of using this technology. However, it could improved with the following suggestions:

Page 4 - Since EB can be caused by mutation in several genes and multiple mutations can be observed within the same patient, strategies correcting a single mutation may not reverse the disease completely. How would some of these studies, which correct a single mutation, translate clinically? Are there any efforts to correct multiple mutations at once using CRISPR?

Page 7 - iPSCs are an attractive tool for cell therapy in some ways because of their low immunogenicity. However, there are several safety concerns with these cells. They could acquire mutations while being expanded in culture and develop into teratomas (Dinella 2014¹). What methods are used to overcome these concerns?

Page 7 - Challenges of therapeutic application should be discussed in more detail. Low efficiency of gene editing is also one of the drawbacks. What are the new techniques being applied to overcome this? (For example, one of the ways to improve the efficiency of HDR is the use of NHEJ inhibitors)

Page 7 - In your discussion of strategies to improve the specificity of Cas9, include the possibility of using several modifications of Cas9 like high-fidelity Cas9 (eSpCas9), evolved Cas9 (evoCas9) in addition to the ones you have mentioned.

References

1. Dinella J, Koster M, Koch P: Use of Induced Pluripotent Stem Cells in Dermatological Research. *Journal of Investigative Dermatology*. 2014; **134** (8): 1-5 [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Partly

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Drug discovery, Immunology, Cancer immunotherapy

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 Sep 2020

Catherine Baker, Geisel School of Medicine at Dartmouth, Hanover, USA

Dear Dr. Hegde,

Thank you for your thoughtful review of our manuscript. We have carefully reviewed the comments and have revised the manuscript accordingly. Our responses are given in a point-by-point manner below.

1. Since EB can be caused by mutation in several genes and multiple mutations can be observed within the same patient, strategies correcting a single mutation may not reverse the disease completely. How would some of these studies, which correct a single mutation, translate clinically? Are there any efforts to correct multiple mutations at once using CRISPR?
 1. A sentence regarding the potential use of CRISPR for targeting rare cases of EB caused by >1 mutation was added to the "Perspectives and future directions" section.
2. iPSCs are an attractive tool for cell therapy in some ways because of their low immunogenicity. However, there are several safety concerns with these cells. They could acquire mutations while being expanded in culture and develop into teratomas (Dinella 2014). What methods are used to overcome these concerns?
 1. The challenges of gene editing with iPSCs are alluded to in the last paragraph of the "Mechanisms of genome engineering with CRISPR-Cas" section.
3. Challenges of therapeutic application should be discussed in more detail. Low efficiency of gene editing is also one of the drawbacks. What are the new techniques being applied to overcome this? (For example, one of the ways to improve the efficiency of HDR is the use of NHEJ inhibitors)
 1. Expanded second paragraph of "Challenges to therapeutic application" to include mention of NHEJ inhibitors and brief mention of other strategies to improve efficiency of Cas9-mediated HDR.
4. In your discussion of strategies to improve the specificity of Cas9, include the possibility of using several modifications of Cas9 like high-fidelity Cas9 (eSpCas9), evolved Cas9 (evoCas9) in addition to the ones you have mentioned.
 1. Cas9 variants with enhanced specificity have been listed as strategies to improve the specificity of Cas9 (second paragraph of "Challenges to therapeutic application" section).

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research